Illumina’s (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?

October 13, 2026 - 11:30

Illumina has climbed 118 percent over the past six months, far outpacing the 21.25 percent gain in the Insider Monkey Billionaire Index and the 14 percent return for the State Street SPDR S&P 500 ETF Trust. The sharp move has forced investors to reconsider a company that spent years wrestling with slowing growth and strategic missteps.

The recovery centers on Illumina's core sequencing business. Demand for genetic analysis tools is stabilizing after a prolonged slump, and the company has moved past several distractions that weighed on its performance. Cost cuts and a tighter focus on its main instruments have helped restore confidence among shareholders who had grown frustrated with the stock.

Still, the rally raises a fair question. A 118 percent jump in six months prices in a lot of good news, and the sequencing market remains competitive. Rivals are pushing cheaper alternatives, and research budgets at universities and hospitals are not growing as fast as they once did. If orders fail to match expectations in the coming quarters, the stock could give back some of its gains.

For now, the momentum favors Illumina. Investors are betting that the worst is over and that the company can convert its dominant position in sequencing into steady revenue growth. Whether that bet pays off depends on execution, not just optimism.